Actively Recruiting
Effects of Quercetin Supplementation on Cardiometabolic Parameters
Led by University of Central Lancashire · Updated on 2026-02-27
40
Participants Needed
1
Research Sites
17 weeks
Total Duration
On this page
Sponsors
U
University of Central Lancashire
Lead Sponsor
D
DoNotAge.org
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of Quercetin supplementation on cardiometabolic health, focusing on conditions like cardiovascular disease and type 2 diabetes mellitus. This trial aims to explore whether Quercetin can improve key health outcomes related to cardiometabolic syndrome, using a randomized, placebo-controlled design to provide clear evidence about its impact. Participants will be randomly assigned to receive either Quercetin tablets (400 mg once daily) or a placebo tablet once daily. The study involves a double-blind setup to ensure unbiased results, comparing the effects of Quercetin against a placebo over the treatment period. During the study, participants will undergo assessments at the start and after 20 days, including measurements of systolic and diastolic blood pressure, body fat percentage, waist-to-hip ratio, blood glucose, cholesterol levels, triglycerides, and various indexes related to metabolism and mental health. Questionnaires assessing depression, anxiety, insomnia, and sleep quality will also be completed. The aim is to monitor changes in these parameters to determine the potential benefits of Quercetin supplementation.
CONDITIONS
Brief Title
Effects of Quercetin on Cardiometabolic Outcomes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy
- Between 18 & 65 years old
- Non-smoker
- Body mass index (BMI) less than 30
- Able to give informed consent
You will not qualify if you...
- Pregnancy
- Diabetes or any other metabolic or uncontrolled hypertensive conditions
- Food allergies to quercetin
- Habitual consumption of quercetin
- Regularly taking medication or antioxidant supplements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 20 days
Participants take either quercetin tablets or placebo once daily and undergo assessments of cardiometabolic parameters.
2 visits (baseline and end of treatment, in-person)
Trial Site Locations
Total: 1 location
1
University of Central Lancashire
Preston, Lancashire, United Kingdom, PR4 0PE
Actively Recruiting
Research Team
J
Jonathan Sinclair, PhD, DSc
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here